In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Argenx Se (ARGX – Research Report), with a price target of $701.00.
Jason Butler’s rating is based on the impressive commercial performance of Argenx’s VYVGART franchise, which has consistently exceeded financial expectations. The company reported strong fourth-quarter results for 2024, with VYVGART net revenues growing significantly, driven by increased sales in the U.S. market. The launch of VYVGART for CIDP has been particularly successful, with a notable increase in new prescribers and patients.
Furthermore, the potential approval of the VYVGART pre-filled syringe in the U.S. is expected to enhance patient access and shift treatment paradigms for MG and CIDP. Argenx’s ongoing efforts in label expansion and pipeline development, including multiple ongoing trials and new studies, underscore its commitment to growth and innovation. With a strong cash position and strategic investments in its pipeline, Argenx is well-positioned for robust free cash flow and continued success, justifying the Buy rating.
According to TipRanks, Butler is an analyst with an average return of -4.4% and a 38.80% success rate. Butler covers the Healthcare sector, focusing on stocks such as Abivax SA Sponsored ADR, Cytokinetics, and Precigen.